GSK's new CEO gets short-term win from generic Advair delay

LONDON (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan's copy of the blockbuster lung inhaler.

Source: Reuters: Health - March 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news